Medlive Technology Co., Ltd. (HK:2192) has released an update.
Medlive Technology Co., Ltd. has extended its collaboration with M3 to provide digital market research and content services until the end of 2027. This agreement, originally set to expire in 2024, allows Medlive to continue offering specialized digital surveys and tailored content for medical professionals. The transaction is considered a continuing connected transaction under Hong Kong’s listing rules, requiring certain disclosures but not independent shareholder approval.
For further insights into HK:2192 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- New York Times’ Striking Tech Guild Returns to Work, Negotiations Continue
- 23andMe Cuts 40% of Staff, Shutters Drug Development Ahead of Q2 Print
- Tesla Option Contracts Gain on Post-Election Rally, Pushing Shares up 9%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
